Abeona Therapeutics Inc (NAS:ABEO)
$ 6.21 0.17 (2.81%) Market Cap: 268.98 Mil Enterprise Value: 162.08 Mil PE Ratio: 0 PB Ratio: 3.53 GF Score: 52/100

Abeona Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 09, 2023 / 01:00PM GMT
Release Date Price: $4.25 (-0.93%)
Maury Raycroft
Jefferies - Analyst

Hi, good morning, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the Abeona team today who's here for a fireside chat, maybe if you want to provide a brief intro to the company, and then we'll jump into questions for the fireside.

Vish Seshadri
Abeona Therapeutics Inc. - CEO & Director

Good morning, everyone, and thank you very much for having us here, Maury. And I am Vish Seshadri, the CEO of Abeona Therapeutics, very happy to share today our company, which is a late clinical-stage, BLA-stage, cell and gene therapy company is advancing EB-101 our lead product candidate in-- for patients with recessive dystrophic EB.

And we're excited that this is a potential one-time therapy that can offer years of clinical benefit for these patients with large chronic wounds. The pipeline, other pipe portfolio products that we have in the preclinical development, our ophthalmology indication based and these are novel capsids in AAV-based gene therapies that address

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot